Palisade Bio, Inc. Share Price
PALIPalisade Bio, Inc. Stock Performance
Open $1.99 | Prev. Close $1.92 | Circuit Range N/A |
Day Range $1.93 - $1.99 | Year Range $0.53 - $2.61 | Volume 10,694 |
Average Traded $1.95 |
Palisade Bio, Inc. Share Price Chart
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Palisade Bio, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Apr-26 | $1.89 | $1.95 | +2.64% |
02-Apr-26 | $1.82 | $1.90 | +0.26% |
01-Apr-26 | $1.76 | $1.89 | +8.00% |
31-Mar-26 | $1.84 | $1.75 | -1.13% |
30-Mar-26 | $1.95 | $1.77 | -11.28% |
27-Mar-26 | $1.94 | $2.00 | +0.76% |
26-Mar-26 | $2.01 | $1.98 | -1.00% |